Berzosertib联合吉西他滨对比吉西他滨单药治疗铂耐药高级别浆液性卵巢癌的随机2期试验
这项多中心、开放标签、随机2期研究纳入70例铂耐药复发高级别浆液性卵巢癌患者,按1:1随机接受吉西他滨单药或吉西他滨联合ATR抑制剂berzosertib治疗。研究认为在吉西他滨基础上加用berzosertib具有获益,值得进一步研究。
要点
- 联合组3-4级血小板减少更常见(24% vs 6%),中性粒细胞减少两组相近。
- 两组各报告1例治疗相关死亡(单药组脓毒症,联合组肺炎)。
核心结论
- 在铂耐药高级别浆液性卵巢癌中,吉西他滨联合berzosertib较吉西他滨单药改善研究者评估的无进展生存期。
- 这是首个在任意瘤种中开展的ATR抑制剂随机研究,联合方案值得进一步研究。
研究设计与样本
- 多中心、开放标签、随机2期研究,由美国Experimental Therapeutics Clinical Trials Network的11个中心开展。
- 纳入70例铂耐药复发高级别浆液性卵巢癌患者,按1:1随机分为吉西他滨单药组(36例)与吉西他滨联合berzosertib组(34例),按无铂间期分层。
主要发现
- 最常见的治疗相关3-4级不良事件为中性粒细胞计数下降(单药组39% vs 联合组47%)和血小板计数下降(6% vs 24%)。
- 严重不良事件见于单药组28%和联合组26%的患者。
关键数值与推荐
- 吉西他滨1000 mg/m2静脉给药,第1天和第8天;berzosertib 210 mg/m2静脉给药,第2天和第9天;21天为一周期,直至疾病进展或不可耐受毒性。
- 主要终点为研究者评估的无进展生存期,分析纳入至少接受一剂研究药物的全部患者。
临床怎么用
- 对铂耐药高级别浆液性卵巢癌,可考虑吉西他滨联合berzosertib作为研究性治疗选择,但需关注血小板减少。
- 该联合方案尚处2期研究阶段,需进一步研究验证后方可常规应用。
局限性
- 开放标签设计,患者和研究者在随机后未设盲,可能影响终点评估。
- 样本量较小(70例),为2期研究,结果需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-grade serous ovarian cancers show increased replication stress, rendering cells vulnerable to ATR inhibition because of near universal loss of the G1/S checkpoint (through deleterious TP53 mutations), premature S phase entry (due to CCNE1 amplification, RB1 loss, or CDKN2A mRNA downregulation), alterations of homologous recombination repair genes, and expression of oncogenic drivers (through MYC amplification and other mechanisms). We hypothesised that the combination of the selective ATR inhibitor, berzosertib, and gemcitabine could show acceptable toxicity and superior efficacy to gemcitabine alone in high-grade serous ovarian cancer. METHODS: In this multicentre, open-label, randomised, phase 2 study, 11 different centres in the US Experimental Therapeutics Clinical Trials Network enrolled women (aged ≥18 years) with recurrent, platinum-resistant high-grade serous ovarian cancer (determined histologically) and Eastern Cooperative Oncology Group performance status of 0 or 1, who had unlimited previous lines of cytotoxic therapy in the platinum-sensitive setting but no more than one line of cytotoxic therapy in the platinum-resistant setting. Eligible patients were randomly assigned (1:1) to receive intravenous gemcitabine (1000 mg/m2) on day 1 and day 8, or gemcitabine plus intravenous berzosertib (210 mg/m2) on day 2 and day 9 of a 21-day cycle until disease progression or intolerable toxicity. Randomisation was done centrally using the Theradex Interactive Web Response System, stratified by platinum-free interval, and with a permuted block size of six. Following central randomisation, patients and investigators were not masked to treatment assignment. The primary endpoint was investigator-assessed progression-free survival, and analyses included all patients who received at least one dose of the study drugs. The study is registered with ClinicalTrials.gov, NCT02595892, and is active but closed to enrolment. FINDINGS: Between Feb 14, 2017, and Sept 7, 2018, 88 patients were assessed for eligibility, of whom 70 were randomly assigned to treatment with gemcitabine alone (36 patients) or gemcitabine plus berzosertib (34 patients). At the data cutoff date (Feb 21, 2020), the median follow-up was 53·2 weeks (25·6-81·8) in the gemcitabine plus berzosertib group and 43·0 weeks (IQR 23·2-69·1) in the gemcitabine alone group. Median progression-free survival was 22·9 weeks (17·9-72·0) for gemcitabine plus berzosertib and 14·7 weeks (90% CI 9·7-36·7) for gemcitabine alone (hazard ratio 0·57, 90% CI 0·33-0·98; one-sided log-rank test p=0·044). The most common treatment-related grade 3 or 4 adverse events were decreased neutrophil count (14 [39%] of 36 patients in the gemcitabine alone group vs 16 [47%] of 34 patients in the gemcitabine plus berzosertib group) and decreased platelet count (two [6%] vs eight [24%]). Serious adverse events were observed in ten (28%) patients in the gemcitabine alone group and nine (26%) patients in the gemcitabine plus berzosertib group. There was one treatment-related death in the gemcitabine alone group due to sepsis and one treatment-related death in the gemcitabine plus berzosertib group due to pneumonitis. INTERPRETATION: To our knowledge, this is the first randomised study of an ATR inhibitor in any tumour type. This study shows a benefit of adding berzosertib to gemcitabine in platinum-resistant high-grade serous ovarian cancer. This combination warrants further investigation in this setting. FUNDING: US National Cancer Institute.
引用
- Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020. PMID: 32553118. doi:10.1016/S1470-2045(20)30180-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。